Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update

/PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...

Related Keywords

United States ,Montreal ,Quebec ,Canada ,Japan ,Japanese ,Americans ,David Bharucha ,David Pitts ,Joseph Oliveto ,Bruce Stambler ,Sean Pokorney ,Duke University School Of Medicine ,Montreal Heart Institute ,Nasdaq ,Arrhythmia Core Laboratory ,Prnewswire Milestone Pharmaceuticals Inc ,Centers For Disease ,Us Securities Exchange Commission ,Milestone Pharmaceuticals Inc ,Arrhythmia Research ,Heart Rhythm Society ,American College Of Cardiology ,Piedmont Heart Institute ,Duke Clinical Research Institute ,Exchange Commission ,Milestone Pharmaceuticals ,Chief Executive Officer ,Heart Rhythm ,Report Topline Data ,Mid Second Half ,New Drug Application ,Label Extension Study ,Key Opinion Leader ,Cardiac Arrhythmia Research ,Assistant Professor ,Duke University School ,Clinical Analysis Evaluating ,Drug Characteristics ,Etripamil Presented ,American College ,Annual Scientific Session ,Chief Medical ,Concept Trial ,Patients Experiencing Atrial Fibrillation ,Rapid Ventricular Rate ,Atrial Fibrillation ,Rapid Ventricular ,Disease Control ,Private Securities Litigation Reform Act ,Nc ,